CurrentKaiser PermanentePolicy N/A

Intense Pulsed Light (IPL) for Meibomian Gland Dysfunction - Clinical Review Criteria

Clinical review criteria governing medical necessity and coverage determinations for IPL treatment of meibomian gland dysfunction for Kaiser Foundation Health Plan of Washington members and providers.

Policy Summary

PayerKaiser Permanente

PolicyIntense Pulsed Light (IPL) for Meibomian Gland Dysfunction - Clinical Review Criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateMar 3, 2026

Key ActionIf requesting review, send the last 6 months of clinical notes from the requesting provider and/or specialist.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

7RCTs reviewed

6RCTs summarized

~20 minSession length

Monthly x4Frequency

Up to 70%MGD prevalence

Coverage Determination

Policy Summary

PayerKaiser Permanente

PolicyIntense Pulsed Light (IPL) for Meibomian Gland Dysfunction - Clinical Review Criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateMar 3, 2026

Key ActionIf requesting review, send the last 6 months of clinical notes from the requesting provider and/or specialist.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Not Medically Necessary / Not Covered

Kaiser Permanente conclusion for IPL in MGD

Not medically necessary conclusion: The evidence is insufficient to demonstrate that IPL is as safe and effective as standard therapies or provides better long-term outcomes; overall evidence does not meet Medical Technology Assessment Criteria.insufficient evidence

Evidence based on six small randomized controlled trials with short follow-up and risk of bias; findings promising but not definitive.

Kaiser Permanente considers the use of Intense Pulsed Light (IPL) for the treatment of meibomian gland dysfunction (MGD) to be not medically necessary. The evidence, consisting mainly of small randomized trials with short follow-up and risk of bias, is insufficient to demonstrate that IPL is as safe and effective as standard therapies or provides superior long-term outcomes; therefore IPL does not meet Kaiser Permanente Medical Technology Assessment criteria.

The following CPT and unlisted procedure codes are considered not medically necessary when billed for IPL treatment of MGD: 0207T, 0507T, 0563T, and 17999 (may be submitted with diagnosis codes H02.88–H02.88B). To verify authorization requirements for a specific code by plan type, use the Pre-authorization Code Check.

Coding and Billing

Considered Not Medically Necessary CPT/Unlisted/ICD-10 CodesmixedNot Covered

0207T	Evacuation of meibomian glands, automated, using heat and intermittent pressure, unilateral
0507T	Near-infrared dual imaging (ie, simultaneous reflective and trans-illuminated light) of meibomian glands, unilateral or bilateral, with interpretation and report
0563T	Evacuation of meibomian glands, using heat delivered through wearable, open-eye eyelid treatment devices and manual gland expression, bilateral
17999	Unlisted procedure, skin, mucous membrane and subcutaneous tissue
H02.88	Meibomian gland dysfunction of eyelid
H02.88B	Meibomian gland dysfunction of eyelid

Provider Actions and Documentation

Denial Risk

Denial Risk: IPL for MGD

Use of Intense Pulsed Light (IPL) for the treatment of meibomian gland dysfunction (MGD) does not meet the Kaiser Permanente Medical Technology/coverage criteria.

IPL for MGD is considered not medically necessary per Kaiser Permanente Medical Technology Assessment.

Documentation Required

Documentation Required for Review

If requesting review for this service, submit the last 6 months of clinical documentation from the requesting provider and/or specialist to support medical necessity.

Last 6 months of clinical notes from requesting provider and/or specialist
Include prior treatments and objective findings relevant to MGD (symptoms, exam, prior therapies and responses).

Note

Conservative Therapy Context

Conservative therapies should be documented and optimized prior to consideration of advanced or experimental procedures. Examples of conservative therapy for meibomian gland dysfunction include artificial tears, application of heat (warm compresses), manual gland expression, topical lubricants often containing fatty acids, omega‑3 supplementation, topical or oral antibiotics, topical corticosteroids, and topical cyclosporine.

Document trials of conservative treatments (type, duration, and response).
Conservative therapies are often temporary and should be exhausted or documented as inadequate before pursuing non‑standard treatments.

Background

Meibomian gland dysfunction (MGD) is an abnormality or obstruction of the eyelid meibomian glands that leads to tear-film instability, increased evaporation, hyperosmolarity and ocular surface inflammation resulting in dry eye symptoms. Risk factors include increasing age, certain ethnicities (higher prevalence reported in some Asian populations), eye makeup and contact lens use. Standard management focuses on conservative therapies such as warm compresses and gland expression, lubricants and topical therapies (eg, antibiotics, corticosteroids, topical cyclosporine), and systemic measures (eg, omega‑3 supplementation). IPL is theorized to benefit MGD by delivering heat to the eyelid skin (wavelengths roughly in the dermatologic IPL range), coagulating abnormal periocular vessels, liquefying inspissated meibum, reducing inflammation, and possibly reducing Demodex, but the exact mechanism and the durability of clinical benefit have not been definitively established.

Definitions

Intense Pulsed Light (IPL) — definition, mechanism, and intended effect

DefinitionIntense Pulsed Light (IPL) is a dermatologic procedure that delivers broad-spectrum pulses of light to skin around the eyelids, applied with eye shields and cooling gel followed by manual meibomian gland expression.

Wavelength rangeApproximately 500–1200 nm.

Primary mechanismsAbsorption by targeted tissue produces heat, coagulates abnormal superficial blood vessels, has antibacterial effects, and may reduce local inflammation and Demodex mites.

Intended effects for MGDHeating and liquefaction of meibum to improve secretion and excretion, occlusion/coagulation of abnormal vessels, reduction of epithelial turnover, photomodulation and collagen activation to reduce ocular surface inflammation and restore normal oil flow.

Procedure steps & typical scheduleEye shields placed, cooling gel applied, pulsed light administered around eyelids, then manual gland expression; procedure duration ≈20 minutes and commonly performed once monthly for four sessions.